By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Protalix Biotherapeutics, Inc. 

2 Snunit Street, Science Park
P.O. Box 455
Karmiel    21000  Israel
Phone: 972-4-988-9488 Fax: 972-4-988-9489


Company News
Protalix (PLX) Announces Presentation Of Phase II Clinical Trial Results For Alidornase Alfa In Cystic Fibrosis At The 40th European Cystic Fibrosis Society Conference 5/23/2017 11:12:54 AM
Protalix (PLX) Announces FDA Investigational New Drug Clearance To Commence Once-Monthly Dosing Study Of Pegunigalsidase Alfa (PRX-102) For The Treatment Of Fabry Disease 5/9/2017 10:35:23 AM
Protalix (PLX) Announces New Preclinical Results Demonstrating A Positive Effect Of Pegunigalsidase Alfa (PRX-102) On Small-Fiber Neuropathy In Fabry Disease Models Compared To Commercially Available Enzyme Replacement Therapies 4/18/2017 11:03:19 AM
Protalix (PLX) Announces Private Note Exchanges And Private Placement Of Secured Convertible Notes Due 2021 12/2/2016 7:14:58 AM
Protalix (PLX) To Present At The Jefferies 2016 Global Healthcare Conference 6/2/2016 10:24:34 AM
Protalix (PLX) Sells Back ELELYSO Rights to Pfizer (PFE) for $46 Million 10/13/2015 6:40:43 AM
Protalix Biotherapeutics, Inc. (PLX) To Explore Non Alcoholic Steato Hepatitis (NASH) As An Indication For Its PRX 106 Oral Anti TNF 10/5/2015 7:26:18 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I/II Interim Clinical Data On The 1mg/Kg Cohort Of PRX-102 For Fabry Disease 9/9/2015 7:18:37 AM
Protalix Biotherapeutics, Inc. (PLX) Reports Second Quarter 2015 Financial Results 8/11/2015 1:08:45 PM
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I Clinical Study Results For PRX-106 Oral Anti-TNF 8/3/2015 7:12:11 AM